Abstract:Biomedical sciences have made major advances in understanding how tissues repair, and the signalling mechanisms required to achieve this goal are progressively being dissected. Advances in the understanding of tissue repair mechanisms and the pivotal role of growth factors have stimulated the use of platelet-rich therapies by orthopaedic surgeons and sports physicians, mainly with the aim of stimulating and enhancing tissue healing. Autologous activated platelets retained in fibrin matrices are used as a source of molecular signals that control cell fate, including cell growth, cell differentiation and the synthesis of diverse functional proteins. Thus far, platelet-rich technologies have spawned additional ambitious endeavours, including surgical and non-surgical treatments in sports orthopaedics. Reconstruction of anterior cruciate ligament and tendon surgery and treatment of joint injuries, tendinopathy or muscle tears are but a few examples of the potential applications of this technology in the field of orthopaedic sports medicine. In the present article, some of the most important therapeutic applications using these approaches - especially preparation rich in growth factor (PRGF) technology - are presented, as are some of the limitations, anti-doping concerns and future challenges in the field. In view of a general state of confusion, the concept of platelet-rich plasma needs rigorous definition associated with well characterized products and re-administration procedures. There is evidence that reconstruction of anterior cruciate ligament and tendon surgery combined with PRGF enhances healing and functional recovery; clinical evidence is also appearing in the literature regarding treatment of tendinopathies and osteoarthritis. Currently, the challenge lies in conducting randomized, controlled clinical trials to determine the essential qualities of these technologies. If anti-doping agencies clarify their regulatory guidelines, robust studies in athletes are expected to emerge. Although much research work lies ahead, the current knowledge points to a future in which platelet-rich therapies will continue improving existing conventional approaches to treatment of sports injuries.

Current Challenges in the Development of Platelet-Rich Plasma-Based Therapies

Platelet-rich plasma and its derivatives as promising bioactive materials for regenerative medicine: basic principles and concepts underlying recent advances

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

The Biological Effect of Enriching the Plasma Content in Platelet-Rich Plasma: An In Vitro Study

Progress in Regenerative Medicine: Exploring Autologous Platelet Concentrates and Their Clinical Applications

Concentrations of Blood Components in Commercial Platelet-Rich Plasma Separation Systems: A Review of the Literature

Freeze-Drying of Platelet-Rich Plasma: The Quest for Standardization

Platelets in wound healing and regenerative medicine

Not all platelet-rich plasma are created equal

Platelet rich plasma. A new treatment tool for the rheumatologist?

A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification

The basic science of platelet-rich plasma (PRP): what clinicians need to know

Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine

Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective

Lights and shadows concerning platelet products for musculoskeletal regeneration

Platelet-Rich Plasma: Fundamentals and Clinical Applications

Systematic Review of Platelet-Rich Plasma in Medical and Surgical Specialties: Quality, Evaluation, Evidence, and Enforcement

Review of concentration yields in commercially available platelet-rich plasma (PRP) systems: a call for PRP standardization

Platelet-rich therapies in the treatment of orthopaedic sport injuries

Platelet-rich plasma in orthopedics: Bridging innovation and clinical applications for bone repair

The use of platelet-rich plasma to treat chronic tendinopathies: A technical analysis